drs. R.S. (Herma) Hamminga

drs. R.S. (Herma) Hamminga

Assistant Professor - medical
  • Gastroenterology and Hepatology

Research Output (118)

Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease

Mahmoud Remi, Schultheiss Hans-Paul, Louwers Jonas, van der Kaaij M T, van Hellemondt B P, Mahmmod N, van Boeckel P G, Jharap B, Fidder Herma, Oldenburg Bas 28 Jan 2022, In: Clinical Gastroenterology and Hepatology. 20 , p. 2577-2587.e6

A Systematic Review with Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease:What Can We Learn from Randomized and Nonrandomized Studies?

Doeve Benthe H., Van De Meeberg Maartje M., Van Schaik Fiona D.M., Fidder Herma H. 1 Oct 2021, In: Journal of Clinical Gastroenterology. 55 , p. 798-809 12 p.

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands

De Bock Ellen, Filipe Mando D., Meij Vincent, Oldenburg Bas, Van Schaik Fiona D.M., Bastian Okan W., Fidder Herma F., Vriens Menno R., Richir Milan C. 2 Jul 2021, In: BMJ Open Gastroenterology. 8

Art in Endoscopy:Dinosaur birth?

Fidder Herma H. 1 Jun 2021, In: Endoscopy. 53 , p. 569 1 p.

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container

Schultheiss Johannes P.D., Altena Sandra, Clevers Max R., Baas Dominique, Jharap Bindia, Fidder Herma H. May 2021, In: Digestive Diseases and Sciences. 66 , p. 1477-1487 11 p.

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease

Mahmmod Shaden, Schultheiss Johannes P D, van Bodegraven Ad A, Dijkstra Gerard, Gilissen Lennard P L, Hoentjen Frank, Lutgens Maurice W M D, Mahmmod Nofel, van der Meulen-de Jong Andrea E, Smits Lisa J T, Tan Adriaan C I T L, Oldenburg Bas, Fidder Herma H 4 Feb 2021, In: Inflammatory bowel diseases. 27 , p. 1954-1962 9 p.

Loss of response to anti-TNF alpha agents depends on treatment duration in patients with inflammatory bowel disease

Schultheiss Johannes P D, Mahmoud Remi, Louwers Jonas M, van der Kaaij Michiel T, van Hellemondt Boris P, van Boeckel Petra G, Mahmmod Nofel, Jharap Bindia, Fidder Herma H, Oldenburg Bas 2021, In: Alimentary Pharmacology & Therapeutics. 54 , p. 1298-1308 11 p.

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events

Asscher Vera E R, van der Vliet Quirine, van der Aalst Karen, van der Aalst Anniek, Brand Eelco C, van der Meulen-de Jong Andrea E, Oldenburg Bas, Pierik Marieke J, van Tuyl Bas, Mahmmod Nofel, Maljaars P W Jeroen, Fidder Herma H, 28 Aug 2020, In: International Journal of Colorectal Disease. 35 , p. 2331-2338 8 p.

Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects

Schultheiss Johannes P D, Brand Eelco C, Lamers Evert, van den Berg Willemijn C M, van Schaik Fiona D M, Oldenburg Bas, Fidder Herma H 16 Jul 2019, In: Alimentary Pharmacology & Therapeutics. 50 , p. 386-396 11 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not